Advertisement
Canadian Journal of Cardiology
Advanced SearchSave search
Training/Practice: Contemporary Issues in Cardiology Practice|Articles in Press

Hearts on fire: the role of inflammation in the pathogenesis of atherosclerotic cardiovascular disease and how we can tend to the flames

  • Kevin E. Boczar
    Correspondence
    Address for correspondence: Dr. Kevin Boczar, MD, FRCPC, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa ON, K1Y 4W7, Tel: +1-6136967334, Fax: +1-613697247
    Affiliations
    Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada

    School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada
    Search for articles by this author
  • Rob Beanlands
    Affiliations
    Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada

    Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada
    Search for articles by this author
Published:May 28, 2022DOI:https://doi.org/10.1016/j.cjca.2022.05.023
Hearts on fire: the role of inflammation in the pathogenesis of atherosclerotic cardiovascular disease and how we can tend to the flames
Previous ArticleDevelopment of a Semiautomated Database for Patients With Adult Congenital Heart Disease
Next ArticleAlirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES∗
      Despite our best attempts to manage traditional cardiovascular (CV) risk factors with contemporary approaches, major adverse cardiac events continue to occur at high rates in patients with established atherosclerotic coronary artery disease (CAD). Inflammation is being increasingly recognized as a major driver, and potential treatment target, of the atherosclerotic disease process. Many physicians are now pondering the question of whether anti-inflammatory agents should enter their toolkit for treating patients with CAD. However, while great strides have been made in the area, more research is needed before anti-inflammatory medications become standard of care for patients with CAD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Ridker P.M.
        • Everett B.M.
        • Thuren T.
        • MacFadyen J.G.
        • Chang W.H.
        • Ballantyne C.
        • et al.
        Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
        N Engl J Med. 2017; 377 (Epub 2017/08/29. doi: 10.1056/NEJMoa1707914. PubMed PMID: 28845751): 1119-1131
        View in Article
        • Tardif J.C.
        • Kouz S.
        • Waters D.D.
        • Bertrand O.F.
        • Diaz R.
        • Maggioni A.P.
        • et al.
        Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
        N Engl J Med. 2019; 381 (Epub 2019/11/17. doi: 10.1056/NEJMoa1912388. PubMed PMID: 31733140): 2497-2505
        View in Article
        • Nidorf S.M.
        • Fiolet A.T.L.
        • Mosterd A.
        • Eikelboom J.W.
        • Schut A.
        • Opstal T.S.J.
        • et al.
        Colchicine in Patients with Chronic Coronary Disease.
        N Engl J Med. 2020; 383 (Epub 2020/09/01. doi: 10.1056/NEJMoa2021372. PubMed PMID: 32865380): 1838-1847
        View in Article
        • Hemkens L.G.
        • Ewald H.
        • Gloy V.L.
        • Arpagaus A.
        • Olu K.K.
        • Nidorf M.
        • et al.
        Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis.
        Heart. 2016; 102 (Epub 2016/02/03. doi: 10.1136/heartjnl-2015-308542. PubMed PMID: 26830663): 590-596
        View in Article
        • Roubille C.
        • Richer V.
        • Starnino T.
        • McCourt C.
        • McFarlane A.
        • Fleming P.
        • et al.
        The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
        Ann Rheum Dis. 2015; 74 (Epub 2015/01/07. doi: 10.1136/annrheumdis-2014-206624. PubMed PMID: 25561362; PubMed Central PMCID: PMCPMC4345910): 480-489
        View in Article

      Article Info

      Publication History

      Accepted: May 25, 2022
      Received in revised form: May 16, 2022
      Received: February 11, 2022

      Publication stage

      In Press Journal Pre-Proof

      Footnotes

      Brief Summary

      Inflammation is being increasingly recognized as a major driver, and potential treatment target, of the atherosclerotic disease process. However, while great strides have been made in this area, more research is needed before anti-inflammatory medications become standard of care for patients with CAD. This paper reviews the current literature on this topic.

      Disclosures

      Kevin Boczar has no disclosures. Rob Beanlands has received honoraria for advisory board activity, with- and is PI or site-PI for research grants from JubilantDraxImage, Lantheus Medical Imaging and GEHealthCare. None of these are considered to pose a conflict of interest for this work.

      Funding

      This review was not supported by any direct funding source. Kevin Boczar is supported by a Canadian Institutes of Health Research Fellowship Award (FRN: 171284). Rob Beanlands is supported as a Distinguished Research Chair in Cardiovascular Imaging by the Faculty of Medicine University of Ottawa and the Division of Cardiology, University of Ottawa Heart Institute.

      Identification

      DOI: https://doi.org/10.1016/j.cjca.2022.05.023

      Copyright

      © 2022 Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX